Current and future therapeutic approaches in progressive supranuclear palsy

Agid, 1987, Progressive supranuclear palsy: anatomoclinical and biochemical considerations, Adv Neurol, 45, 191 Albanese, 2003, Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists, Acta Neurol Scand, 107, 349, 10.1034/j.1600-0404.2003.02049.x Albers, 2002, Mitochondrial dysfunction in progressive supranuclear palsy, Neurochem Int, 40, 559, 10.1016/S0197-0186(01)00126-7 Albers, 1999, Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy, J Neurochem, 73, 881, 10.1046/j.1471-4159.1999.0730881.x Albers, 2000, Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment, J Neurochem, 74, 878, 10.1046/j.1471-4159.2000.740878.x Albert, 1974, The ‘subcortical dementia’ of progressive supranuclear palsy, J Neurol Neurosurg Psychiatry, 37, 121, 10.1136/jnnp.37.2.121 Alexander, 1986, Parallel organization of functionally segregated circuits linking basal ganglia and cortex, Annu Rev Neurosci, 9, 357, 10.1146/annurev.ne.09.030186.002041 Asahina, 1998, Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study, J Neurol Neurosurg Psychiatry, 65, 155, 10.1136/jnnp.65.2.155 Asanuma, 1993, A case of progressive supranuclear palsy showing marked improvements of frontal hypoperfusion, as well as parkinsonism with amitriptyline, Rinsho Shinkeigaku, 33, 317 Barclay, 1997, Dystonia in progressive supranuclear palsy, J Neurol Neurosurg Psychiatry, 62, 352, 10.1136/jnnp.62.4.352 Barclay, 1996, Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy, Neurology, 46, 1284, 10.1212/WNL.46.5.1284 Beal, 2002, Coenzyme Q10 as a possible treatment for neurodegenerative diseases, Free Radic Res, 36, 455, 10.1080/10715760290021315 Beal, 2003, Bioenergetic approaches for neuroprotection in Parkinson's disease, Ann Neurol, 53, S39, 10.1002/ana.10479 Beal, 2004, Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment, J Bioenerg Biomembr, 36, 381, 10.1023/B:JOBB.0000041772.74810.92 Birdi, 2002, Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases, Mov Disord, 17, 1255, 10.1002/mds.10211 Blesch, 2004, Gene therapy and cell transplantation for Alzheimer's disease and spinal cord injury, Yonsei Med J, 45, 28, 10.3349/ymj.2004.45.Suppl.28 Blin, 1995, Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?, Brain, 118, 1485, 10.1093/brain/118.6.1485 Brusa, 2004, Delayed administration may improve entacapone effects in parkinsonian patients non‐responding to the drug, Eur J Neurol, 11, 593, 10.1111/j.1468-1331.2004.00860.x Buee, 2000, Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res Brain Res Rev, 33, 95, 10.1016/S0165-0173(00)00019-9 Bugiani, 1979, The fine structure of subcortical neurofibrillary tangles in progressive supranuclear palsy, Acta Neuropathol, 45, 147, 10.1007/BF00691893 Buhot, 1997, Serotonin receptors in cognitive behaviors, Curr Opin Neurobiol, 7, 243, 10.1016/S0959-4388(97)80013-X Cakmur, 2002, Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm, J Neurol, 249, 64, 10.1007/PL00007849 Carrilho, 2002, Progressive supranuclear palsy in a sample of Brazilian population: clinical features of 16 patients, Arq Neuropsiquiatr, 60, 917, 10.1590/S0004-282X2002000600006 Chauhan, 2005, Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576, Neuropharmacology, 48, 93, 10.1016/j.neuropharm.2004.09.014 Chen, 2005, Clinical pharmacology of rasagiline: a novel, second‐generation propargylamine for the treatment of Parkinson disease, J Clin Pharmacol, 45, 878, 10.1177/0091270005277935 Chiu, 1996, Progressive supranuclear palsy presenting with psychiatric features, Br J Clin Pract, 50, 60, 10.1111/j.1742-1241.1996.tb10025.x Choi‐Kwon, 2006, Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double‐blind, placebo‐controlled study, Stroke, 37, 156, 10.1161/01.STR.0000190892.93663.e2 Collins, 1995, Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria, J Neurol Neurosurg Psychiatry, 58, 167, 10.1136/jnnp.58.2.167 Cordivari, 2001, Treatment of dystonic clenched fist with botulinum toxin, Mov Disord, 16, 907, 10.1002/mds.1186 Cordivari, 2004, New therapeutic indications for botulinum toxins, Mov Disord, 19, S157, 10.1002/mds.20071 Cummings, 1993, Frontal‐subcortical circuits and human behavior, Arch Neurol, 50, 873, 10.1001/archneur.1993.00540080076020 D'Antona, 1985, Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy, Brain, 108, 785, 10.1093/brain/108.3.785 2002, Ergot derivatives: lisuride: management of Parkinson's disease, Mov Disord, 17, S74, 10.1002/mds.5565 Daniele, 1999, Zolpidem in progressive supranuclear palsy, N Engl J Med, 341, 543, 10.1056/NEJM199908123410721 Davie, 1997, Proton magnetic resonance spectroscopy in Steele‐Richardson‐Olszewski syndrome, Mov Disord, 12, 767, 10.1002/mds.870120525 Defazio, 1999, “Apraxia of eyelid opening” induced by levodopa therapy and apomorphine in atypical parkinsonism (possible progressive supranuclear palsy) a case report, Clin Neuropharmacol, 22, 292 Dehaene, 1970, L‐dopa in progressive supranuclear palsy, Lancet, 2, 470, 10.1016/S0140-6736(70)90089-9 Destee, 1990, Obsessive‐compulsive behavior and progressive supranuclear palsy, Rev Neurol (Paris), 146, 12 Diroma, 2003, Natural history and clinical features of progressive supranuclear Palsy: a clinical study, Neurol Sci, 24, 176, 10.1007/s10072-003-0117-z Donaldson, 1973, The treatment of progressive supranuclear palsy with L‐dopa, Aust N Z J Med, 3, 413, 10.1111/j.1445-5994.1973.tb03116.x Dou, 2003, Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus‐1 encephalitis, J Neurosci, 23, 9162, 10.1523/JNEUROSCI.23-27-09162.2003 Dubas, 1983, Steele‐Richardson‐Olszewski disease without ophthalmoplegia. 6 clinico‐anatomic cases, Rev Neurol (Paris), 139, 407 Duncombe, 1985, Methysergide in progressive supranuclear palsy, Neurology, 35, 936, 10.1212/WNL.35.6.936 Engel, 1996, Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects, J Am Geriatr Soc, 44, 1072, 10.1111/j.1532-5415.1996.tb02940.x Esmonde, 1996, Progressive supranuclear palsy presenting with dynamic aphasia, J Neurol Neurosurg Psychiatry, 60, 403, 10.1136/jnnp.60.4.403 Fabbrini, 2001, Donepezil in the treatment of progressive supranuclear palsy, Acta Neurol Scand, 103, 123, 10.1034/j.1600-0404.2001.103002123.x Factor, 2001, Long‐term comparative experience with tolcapone and entacapone in advanced Parkinson's disease, Clin Neuropharmacol, 24, 295, 10.1097/00002826-200109000-00007 Federico, 1997, Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy, J Neurol Neurosurg Psychiatry, 62, 239, 10.1136/jnnp.62.3.239 Federico, 1997, Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders, Mov Disord, 12, 903, 10.1002/mds.870120611 Fjord‐Larsen, 2005, Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct, Exp Neurol, 195, 49, 10.1016/j.expneurol.2005.03.006 Foster, 1989, Failure of cholinergic agonist RS‐86 to improve cognition and movement in PSP despite effects on sleep, Neurology, 39, 257, 10.1212/WNL.39.2.257 Frampton, 2003, Propentofylline for dementia, Cochrane Database Syst Rev, 2, CD002853 Frattali, 1999, Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy, A pilot study. Dysphagia, 14, 165, 10.1007/PL00009600 Fujino, 2002, [Clinical effectiveness of tandospirone citrate (5‐HT1A agonist) on patients with progressive supranuclear palsy], Rinsho Shinkeigaku, 42, 42 Gash, 2005, Trophic factor distribution predicts functional recovery in parkinsonian monkeys, Ann Neurol, 58, 224, 10.1002/ana.20549 Ghika, 1991, Idazoxan treatment in progressive supranuclear palsy, Neurology, 41, 986, 10.1212/WNL.41.7.986 Giladi, 2001, The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study, J Neurol, 248, 572, 10.1007/s004150170134 Goetz, 1989, Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease, N Engl J Med, 320, 337, 10.1056/NEJM198902093200601 Goetz, 2003, Progression of gait, speech and swallowing deficits in progressive supranuclear palsy, Neurology, 60, 917, 10.1212/01.WNL.0000052686.97625.27 Grafman, 1990, Frontal lobe function in progressive supranuclear palsy, Arch Neurol, 47, 553, 10.1001/archneur.1990.00530050077015 Gross, 1969, L‐dopa for progressive supranuclear palsy, Lancet, 2, 1359 Haldeman, 1981, Progressive supranuclear palsy, computed tomography, and response to antiparkinsonian drugs, Neurology, 31, 442, 10.1212/WNL.31.4.442 Hardman, 1999, The external globus pallidus in patients with Parkinson's disease and progressive supranuclear palsy, Mov Disord, 14, 626, 10.1002/1531-8257(199907)14:4<626::AID-MDS1012>3.0.CO;2-U Hardman, 1999, The internal globus pallidus is affected in progressive supranuclear palsy and Parkinson's disease, Exp Neurol, 158, 135, 10.1006/exnr.1999.7072 Haria, 1994, A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders, Drugs Aging, 4, 331, 10.2165/00002512-199404040-00006 Hauser, 1994, Initial experience with electroconvulsive therapy for progressive supranuclear palsy, Mov Disord, 9, 467, 10.1002/mds.870090419 Hauw, 1994, Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy), Neurology, 44, 2015, 10.1212/WNL.44.11.2015 Hughes, 1990, Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes, Lancet, 336, 32, 10.1016/0140-6736(90)91531-E Iannaccone, 1996, Pharmacologic treatment of emotional lability, Clin Neuropharmacol, 19, 532, 10.1097/00002826-199619060-00008 Iijima, 2001, [A case of progressive supranuclear palsy improved with tandospirone citrate], Rinsho Shinkeigaku, 41, 150 Izzo, 1986, Rehabilitation in progressive supranuclear palsy: case report, Arch Phys Med Rehabil, 67, 473 Jackson, 1983, Progressive supranuclear palsy: clinical features and response to treatment in 16 patients, Ann Neurol, 13, 273, 10.1002/ana.410130308 Jankovic, 1983, Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy, Neurology, 33, 505, 10.1212/WNL.33.4.505 Jankovic, 1996, Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening, J Neurol Neurosurg Psychiatry, 60, 704, 10.1136/jnnp.60.6.704 Jenkins, 1969, L‐dopa for progressive supranuclear palsy, Lancet, 2, 742, 10.1016/S0140-6736(69)90449-8 Jope, 2004, The glamour and gloom of glycogen synthase kinase‐3, Trends Biochem Sci, 29, 95, 10.1016/j.tibs.2003.12.004 Kato, 1994, [A case of progressive supranuclear palsy showing improvement of rigidity, nuchal dystonia and autonomic failure with trazodone], Rinsho Shinkeigaku, 34, 1013 Keating, 2005, Tolcapone: a review of its use in the management of Parkinson's disease, CNS Drugs, 19, 165, 10.2165/00023210-200519020-00006 Kertzman, 1990, Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy, Arch Neurol, 47, 1346, 10.1001/archneur.1990.00530120092016 Kish, 1985, Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers, Ann Neurol, 18, 530, 10.1002/ana.410180504 Klawans, 1969, L‐dopa for progressive supranuclear palsy, Lancet, 2, 1359, 10.1016/S0140-6736(69)90892-7 Koller, 1989, Autologous adrenal medullary transplant in progressive supranuclear palsy, Neurology, 39, 1066, 10.1212/WNL.39.8.1066 Koller, 2005, An open‐label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing‐off, J Neural Transm, 112, 221, 10.1007/s00702-004-0184-1 Kompoliti, 1998, Pharmacological therapy in progressive supranuclear palsy, Arch Neurol, 55, 1099, 10.1001/archneur.55.8.1099 Kovacs, 2003, Nucleus‐specific alteration of raphe neurons in human neurodegenerative disorders, Neuroreport, 14, 73, 10.1097/00001756-200301200-00014 Kuhn, 2004, Patterns of abnormal motor cortex excitability in atypical parkinsonian syndromes, Clin Neurophysiol, 115, 1786, 10.1016/j.clinph.2004.03.020 Kvale, 1982, Amitriptyline in the management of progressive supranuclear palsy, Arch Neurol, 39, 387, 10.1001/archneur.1982.00510180065029 Laffont, 1988, Sleep abnormalities and evoked potentials (VEP‐BAER‐SEP) in progressive supranuclear palsy, Neurophysiol Clin, 18, 255, 10.1016/S0987-7053(88)80030-3 Lang, 2005, Treatment of progressive supranuclear palsy and corticobasal degeneration, Mov Disord, 20, S83, 10.1002/mds.20545 Le, 2001, Are dopamine receptor agonists neuroprotective in Parkinson's disease?, Drugs Aging, 18, 389, 10.2165/00002512-200118060-00001 Levy, 1995, Alterations of gabaergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA, Neurology, 45, 127, 10.1212/WNL.45.1.127 Limke, 2003, Neural stem cell therapy in the aging brain: pitfalls and possibilities, J Hematother Stem Cell Res, 12, 615, 10.1089/15258160360732641 Lin, 2003, Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation, Am J Pathol, 162, 213, 10.1016/S0002-9440(10)63812-6 Litvan, 2001, Diagnosis and management of progressive supranuclear palsy, Semin Neurol, 21, 41, 10.1055/s-2001-13118 Litvan, 1992 Litvan, 1989, Physostigmine treatment of progressive supranuclear palsy, Ann Neurol, 26, 404, 10.1002/ana.410260318 Litvan, 1994, Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy, Ann Neurol, 36, 55, 10.1002/ana.410360112 Litvan, 1996, Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele‐Richardson‐Olszewski syndrome) report of the NINDS‐SPSP international workshop, Neurology, 47, 1, 10.1212/WNL.47.1.1 Litvan, 1997, Characterizing swallowing abnormalities in progressive supranuclear palsy, Neurology, 48, 1654, 10.1212/WNL.48.6.1654 Litvan, 1998, Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders, Arch Neurol, 55, 1313, 10.1001/archneur.55.10.1313 Litvan, 2001, Randomized placebo‐controlled trial of donepezil in patients with progressive supranuclear palsy, Neurology, 57, 467, 10.1212/WNL.57.3.467 Losada Baltar, 2004, [Differential efficacy of two psychoeducational interventions for dementia family caregivers], Rev Neurol, 38, 701 Marra, 2003, Progressive supranuclear palsy: analysis of six cases, Neurol Sci, 24, 186, 10.1007/s10072-003-0122-2 Mattson, 1997, 4‐Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule‐associated protein tau, Neuroreport, 8, 2275, 10.1097/00001756-199707070-00036 Mayr, 2002, Zolpidem in progressive supranuclear palsy, Eur J Neurol, 9, 184, 10.1046/j.1468-1331.2002.0354g.x Mendell, 1970, Modification by L‐dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism, Lancet, 1, 593, 10.1016/S0140-6736(70)91629-6 Metter, 1986, Clinical and acoustical variability in hypokinetic dysarthria, J Commun Disord, 19, 347, 10.1016/0021-9924(86)90026-2 Morariu, 1979, Progressive supranuclear palsy and normal‐pressure hydrocephalus, Neurology, 29, 1544, 10.1212/WNL.29.11.1544 Muller, 2002, Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia, J Neurol, 249, 300, 10.1007/s004150200009 Nagasaka, 1997, Aniracetam for treatment of patients with progressive supranuclear palsy, Eur Neurol, 37, 195, 10.1159/000117437 Nakashima, 2005, Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies, Acta Neuropathol (Berl), 110, 547, 10.1007/s00401-005-1087-4 Nath, 2003, Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study, Neurology, 60, 910, 10.1212/01.WNL.0000052991.70149.68 Neophytides, 1982, The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy, J Neurol Neurosurg Psychiatry, 45, 261, 10.1136/jnnp.45.3.261 Netzel, 2001, Electroconvulsive therapy‐responsive depression in a patient with progressive supranuclear palsy, J Ect, 17, 68, 10.1097/00124509-200103000-00015 Newman, 1985, Treatment of progressive supranuclear palsy with tricyclic antidepressants, Neurology, 35, 1189, 10.1212/WNL.35.8.1189 Nieforth, 1993, Retrospective study of drug response in 87 patients with progressive supranuclear palsy, Clin Neuropharmacol, 16, 338, 10.1097/00002826-199308000-00006 Nitrini, 1987, Elementary motor perservation in early diagnosis of progressive supranuclear palsy, Arq Neuropsiquiatr, 45, 29, 10.1590/S0004-282X1987000100004 Noble, 2005, Inhibition of glycogen synthase kinase‐3 by lithium correlates with reduced tauopathy and degeneration in vivo, Proc Natl Acad Sci U S A, 102, 6990, 10.1073/pnas.0500466102 Nutt, 2003, Randomized, double‐blind trial of glial cell line‐derived neurotrophic factor (GDNF) in PD, Neurology, 60, 69, 10.1212/WNL.60.1.69 Odetti, 2000, Lipoperoxidation is selectively involved in progressive supranuclear palsy, J Neuropathol Exp Neurol, 59, 393, 10.1093/jnen/59.5.393 Okun, 2005, Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers, Arch Neurol, 62, 1250, 10.1001/archneur.62.8.noc40425 Olanow, 2005, Double‐blind, placebo‐controlled trials for surgical interventions in Parkinson disease, Arch Neurol, 62, 1343, 10.1001/archneur.62.9.1343 Ondo, 2004, A double‐blind placebo‐controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease, Neurology, 62, 37, 10.1212/01.WNL.0000101713.81253.4C Ota, 2005, Pure akinesia presenting with antecollis, No To Shinkei, 57, 893 Paija, 2005, Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR, Clin Neuropharmacol, 28, 115, 10.1097/01.wnf.0000166393.33781.87 Papapetropoulos, 2005, Natural history of progressive supranuclear palsy: a clinicopathologic study from a population of brain donors, Eur Neurol, 54, 1, 10.1159/000086754 Parkes, 1981, Lisuride in parkinsonism, Ann Neurol, 9, 48, 10.1002/ana.410090109 Pascual, 1993, Autoradiographic demonstration of loss of alpha 2‐adrenoceptors in progressive supranuclear palsy: preliminary report, J Neurol Sci, 114, 165, 10.1016/0022-510X(93)90293-8 Patel, 2005, Intraputamenal infusion of glial cell line‐derived neurotrophic factor in PD: a two‐year outcome study, Ann Neurol, 57, 298, 10.1002/ana.20374 Paulson, 1981, Progressive supranuclear palsy: pneumoencephalography, electronystagmography and treatment with methysergide, Eur Neurol, 20, 13, 10.1159/000115198 Perkin, 1978, Problems in the diagnosis of progressive supranuclear palsy. (Steele‐Richardson‐Olszewski syndrome), Can J Neurol Sci, 5, 168, 10.1017/S0317167100024501 Pfaffenbach, 1972, Ocular manifestations in progressive suprauclear palsy, Am J Ophthalmol, 74, 1179, 10.1016/0002-9394(72)90740-4 Pinhas, 1978, Progressive supranuclear palsy: electomyographic examinations of eyes muscles, Acta Neurol Scand, 58, 304, 10.1111/j.1600-0404.1978.tb02891.x Plaha, 2005, Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease, Neuroreport, 16, 1883, 10.1097/01.wnr.0000187637.20771.a0 Rafal, 1981, Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents, Neurology, 31, 1507, 10.1212/WNL.31.12.1507 Rascol, 1998, Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy, Mov Disord, 13, 673, 10.1002/mds.870130411 Reynolds, 2005, Rotigotine: in Parkinson's disease, CNS Drugs, 19, 973, 10.2165/00023210-200519110-00006 Sacks, 1969, L‐dopa for progressive suparanuclear palsy, Lancet, 2, 591, 10.1016/S0140-6736(69)90284-0 Sandyk, 1998, Transcranial AC pulsed applications of weak electromagnetic fields reduces freezing and falling in progressive supranuclear palsy: a case report, Int J Neurosci, 94, 41, 10.3109/00207459808986437 Sandyk, 1985, Naloxone in progressive supranuclear palsy, Clin Neuropharmacol, 8, 198, 10.1097/00002826-198506000-00014 Sanftner, 2005, AAV2‐mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters, Exp Neurol, 194, 476, 10.1016/j.expneurol.2005.03.007 Schainker, 1978, Autopsy diagnosis of progressive supranuclear palsy mistaken clinically for stroke, Case report. Mo Med, 75, 227 Schneider, 1989, Progressive supranuclear palsy with agitation: response to trazodone but not to thiothixine or carbamazepine, J Geriatr Psychiatry Neurol, 2, 109, 10.1177/089198878900200212 Shinotoh, 1999, Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy, Ann Neurol, 46, 62, 10.1002/1531-8249(199907)46:1<62::AID-ANA10>3.0.CO;2-P Shinotoh, 2001, In vivo mapping of brain cholinergic function in Parkinson's disease and progressive supranuclear palsy, Adv Neurol, 86, 249 Silveira‐Moriyama, 2005, Botulinum toxin a in the treatment of blepharospasm: a 10‐year experience, Arq Neuropsiquiatr, 63, 221, 10.1590/S0004-282X2005000200006 Skogseid, 2005, The course of cervical dystonia and patient satisfaction with long‐term botulinum toxin A treatment, Eur J Neurol, 12, 163, 10.1111/j.1468-1331.2004.01053.x Steele, 1964, Progressive supranuclear palsy. a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia, Arch Neurol, 10, 333, 10.1001/archneur.1964.00460160003001 Stefani, 2007, Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease, Brain, 130, 1596, 10.1093/brain/awl346 Sugaya, 2003, Neuroreplacement therapy and stem cell biology under disease conditions, Cell Mol Life Sci, 60, 1891, 10.1007/s00018-002-3014-y Suteerawattananon, 2002, Supported treadmill training for gait and balance in a patient with progressive supranuclear palsy, Phys Ther, 82, 485, 10.1093/ptj/82.5.485 Tamai, 1997, Nortriptyline for the treatment of depression in progressive supranuclear palsy, J Am Geriatr Soc, 45, 1033, 10.1111/j.1532-5415.1997.tb02984.x Tedeschi, 1997, Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration, Brain, 120, 1541, 10.1093/brain/120.9.1541 Tetrud, 1996, Autopsy‐proven progressive supranuclear palsy in two siblings, Neurology, 46, 931, 10.1212/WNL.46.4.931 Tuszynski, 2005, A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease, Nat Med, 11, 551, 10.1038/nm1239 Wagshul, 1969, L-dopa for progressive supranuclear palsy, Lancet, 2, 105, 10.1016/S0140-6736(69)92413-1 Uttl, 1998, Caregiving in progressive supranuclear palsy, Neurology, 51, 1303, 10.1212/WNL.51.5.1303 Vu, 2000, Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6‐hydroxydopamine, J Neural Transm, 107, 159, 10.1007/s007020050014 Van Balken, 2006, Current and future treatments in progressive supranuclear palsy, Curr Treat Options Neurol, 8, 211, 10.1007/s11940-006-0012-z Ward‐Smith, 1990, Autologous transplantation as a treatment for progressive supranuclear palsy, J Neurosci Nurs, 22, 100, 10.1097/01376517-199004000-00008 Weiner, 1999, Pramipexole in progressive supranuclear palsy, Neurology, 52, 873, 10.1212/WNL.52.4.873 Whitehouse, 1988, Reductions in acetylcholine and nicotine binding in several degenerative diseases, Arch Neurol, 45, 722, 10.1001/archneur.1988.00520310028012 Williams, 1979, Actions of bromocriptine in the Shy‐Drager and Steele‐Richardson‐Olszewski syndromes, 271 Yamamoto, 1997, Result of long‐term administration of L‐threo‐3,4‐dihydroxyphenylserine in patients with pure akinesia as an early symptom of progressive supranuclear palsy, Clin Neuropharmacol, 20, 371, 10.1097/00002826-199708000-00010 Yamashi, 1986, [Short‐term treatment of progressive supranuclear palsy with amitriptyline], Rinsho Shinkeigaku, 26, 1138 Yokoji, 1997, [A case of progressive supranuclear palsy associated with bilateral vocal cord abductor paralysis], Rinsho Shinkeigaku, 37, 523 Yoshikawa, 1997, Pure akinesia manifested neuroleptic malignant syndrome: a clinical variant of progressive supranuclear palsy, Acta Neuropathol (Berl), 93, 306, 10.1007/s004010050619 Youdim, 2004, A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease, Neurology, 63, S32, 10.1212/WNL.63.7_suppl_2.S32 Young, 1985, Progressive supranuclear palsy: postmortem chemical analysis, Ann Neurol, 18, 521, 10.1002/ana.410180502 Yukitake, 1996, Improvement of ophthalmoplegia by 5‐hydroxytryptophan in two cases of progressive supranuclear palsy, Rinsho Shinkeigaku, 36, 906 Zou, 2000, Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in C57BL/6 mice, Neurosci Lett, 281, 167, 10.1016/S0304-3940(00)00853-3 2002, Ergot derivatives: pergolide: management of Parkinson's disease, Mov Disord, 17, S79, 10.1002/mds.5566